Effectiveness of Erbium: YAG Laser in the Treatment of Vulvovaginal Atrophy in Women Who Survived Breast Cancer
Journal of Cosmetic Dermatology · 2025-09 · 24 (9)
DOI: 10.1111/jocd.70424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 12.09.2025. Verfasst von Keila Seabra Teles Ferreira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Post-Graduation, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil. Hauptthemen laut MEDLINE: Lasers, Solid-State, Breast Neoplasms, Vagina, Cancer Survivors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, PROBIC-Scientific Initiation Grants for Medical Students of FCMMG and FELUMA.
Abstract (Originalsprache)
Background
Genitourinary syndrome of menopause (GSM) is prevalent among breast cancer survivors (BCS), often exacerbated by oncologic treatments and compounded by contraindications to hormone‐based therapies. Vaginal Erbium:YAG laser has emerged as a promising non‐hormonal alternative, though long‐term safety and efficacy data remain scarce.
Methods
This prospective pilot study initially enrolled twelve breast cancer survivors (BCS) presenting with moderate to severe genitourinary syndrome of menopause (GSM). The study consisted of two phases: in phase 1, patients underwent 3 monthly sessions of fractional Erbium:YAG (erbium: yttrium‐aluminum garnet) laser and were evaluated before the first laser and 1 month after the third session. In Phase 2, patients were evaluated 1 year after the beginning of the treatment (first laser session). Clinical evaluations were carried out at baseline and after each study phase using the Vaginal Health Index (VHI), the Female Sexual Function Index (FSFI), and a customized Symptom Intensity Questionnaire. Vaginal biopsies and cytological samples were obtained at baseline and at the end of the first phase. H&E staining, Picrosirius Red, glycogen deposits, and epithelial thickness were evaluated in all samples. A Likert scale was administered at the end of each phase to assess patient satisfaction. Statistical analyses were performed using paired t ‐tests, bootstrap resampling techniques, and logistic regression models to evaluate treatment outcomes and response predictors.
Results
12 patients enrolled in the study, ten completed phase one, and eight completed Phase 2. Mean VHI scores improved significantly from 10.75 ± 2.4 to 23.38 ± 3.1 ( p < 0.0001). Symptom severity decreased significantly ( p = 0.0078). FSFI scores showed clinical improvement (from 15.52 ± 7.20 to 25.05 ± 6.81), though not statistically significant ( p = 0.0889); bootstrap and simulation analyses confirmed robustness. Histological findings indicated epithelial remodeling without adverse tissue effects. All patients gave the best satisfaction scores to the treatment (Likert = 5). No adverse events were reported.
Conclusions
Vaginal Erbium:YAG laser therapy appears to be a safe and potentially effective option for GSM management in BCS. Further randomized controlled trials are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Post-Graduation, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil.
- Division of Country Health Policies and Systems (CPS), World Health Organization Regional Office for Europe, Copenhagen, Denmark.
- Department of Internal Medicine at the School of Medicine and Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Pathology, Clinical Hospital of the Federal University of Minas Gerais, Belo Horizonte, Brazil.
- Department of Dermatology, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Gisele Viana de Oliveira
Förderung
- World Health Organization
- PROBIC-Scientific Initiation Grants for Medical Students of FCMMG and FELUMA
Zitieren
APA
Ferreira, K. S. T., Lopes, G. A., Barbosa, L. A., do Nascimento, I. J. B., Pedrosa, M. S., Kroumpouzos, G., & de Oliveira, G. V. (2025). Effectiveness of Erbium: YAG Laser in the Treatment of Vulvovaginal Atrophy in Women Who Survived Breast Cancer. Journal of Cosmetic Dermatology, 24(9). https://doi.org/10.1111/jocd.70424
Vancouver
Ferreira KST, Lopes GA, Barbosa LA, do Nascimento IJB, Pedrosa MS, Kroumpouzos G, et al. Effectiveness of Erbium: YAG Laser in the Treatment of Vulvovaginal Atrophy in Women Who Survived Breast Cancer. Journal of Cosmetic Dermatology. 2025;24(9). doi:10.1111/jocd.70424
BibTeX
@article{Ferreira2025,
author = {Ferreira, Keila Seabra Teles and Lopes, Giovanna Andrade and Barbosa, Letícia Alves and do Nascimento, Israel Júnior Borges and Pedrosa, Moisés Salgado and Kroumpouzos, George and de Oliveira, Gisele Viana},
title = {Effectiveness of Erbium: YAG Laser in the Treatment of Vulvovaginal Atrophy in Women Who Survived Breast Cancer},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
volume = {24},
number = {9},
doi = {10.1111/jocd.70424}
}
EUVIMED